Skip to content

H.R. 1092 · 118th Congress (2023–2025)

BENEFIT Act of 2023

This bill requires the Food and Drug Administration (FDA) to consider relevant patient experience data in the risk-benefit assessment framework used in the process for approving new drugs.

After a new drug application has been approved, the FDA's public statement about how it used patient experience data shall include a description of how such data was considered in the risk-benefit assessment framework.

Show official title

To strengthen the use of patient-experience data within the benefit-risk framework for approval of new drugs.

Expired in House committee

Derived from the legislative history, not an official disposition.

Latest actionReferred to Health

This bill’s path

This is H.R. 1092’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

  6. Expired

Sponsor
Rep. Doris O. Matsui (D-CA-7)
Cosponsors
31 cosponsors

1 original · 30 later

16 R · 15 D

  1. Rep. Brad R. Wenstrup (R-OH-2)· Original · Feb 17, 2023
  2. Rep. Gus M. Bilirakis (R-FL-12)· Later · Mar 21, 2023
  3. Rep. Chellie Pingree (D-ME-1)· Later · Apr 10, 2023
  4. Rep. Rudy Yakym III (R-IN-2)· Later · Apr 10, 2023
  5. Rep. Mark E. Green (R-TN-7)· Later · Apr 13, 2023
  6. Rep. Deborah K. Ross (D-NC-2)· Later · Apr 18, 2023
  7. Rep. Tim Burchett (R-TN-2)· Later · Apr 19, 2023
  8. Rep. Jared F. Golden (D-ME-2)· Later · May 2, 2023
  9. Rep. Don Bacon (R-NE-2)· Later · Sep 8, 2023
  10. Rep. Emanuel Cleaver (D-MO-5)· Later · Sep 8, 2023
  11. Rep. Susan Wild (D-PA-7)· Later · Sep 8, 2023
  12. Rep. Tony Cárdenas (D-CA-29)· Later · Sep 26, 2023
  13. Rep. Brian K. Fitzpatrick (R-PA-1)· Later · Sep 26, 2023
  14. Rep. Josh Harder (D-CA-9)· Later · Sep 26, 2023
  15. Rep. Brian Higgins (D-NY-26)· Later · Oct 10, 2023
  16. Del. Eleanor Holmes Norton (D-DC)· Later · Oct 10, 2023
  17. Rep. Shri Thanedar (D-MI-13)· Later · Oct 10, 2023
  18. Rep. Dean Phillips (D-MN-3)· Later · Oct 12, 2023
  19. Rep. Tom Cole (R-OK-4)· Later · Oct 18, 2023
  20. Rep. Josh Gottheimer (D-NJ-5)· Later · Oct 30, 2023
  21. Rep. Jefferson Van Drew (R-NJ-2)· Later · Dec 5, 2023
  22. Res. Comm. Jenniffer González-Colón (R-PR)· Later · Dec 22, 2023
  23. Rep. Doug LaMalfa (R-CA-1)· Later · Jan 29, 2024
  24. Rep. Michael Lawler (R-NY-17)· Later · Mar 7, 2024
  25. Rep. John James (R-MI-10)· Later · Mar 19, 2024
  26. Rep. Glenn Thompson (R-PA-15)· Later · Mar 19, 2024
  27. Rep. Debbie Wasserman Schultz (D-FL-25)· Later · May 21, 2024
  28. Rep. Paul Tonko (D-NY-20)· Later · May 22, 2024
  29. Rep. Greg Landsman (D-OH-1)· Later · Jun 7, 2024
  30. Rep. Troy Balderson (R-OH-12)· Later · Jun 26, 2024
  31. Rep. Glenn Grothman (R-WI-6)· Later · Sep 25, 2024
Policy area
Health

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. Latest
    ▸ 2 committee actions · Feb 17, 2023 – Feb 24, 2023
    1. Referred to committee

      Referred to the House Committee on Energy and Commerce.

      Sources
    2. Referred to Health

      Referred to the Subcommittee on Health.

      Sources
  3. Expired

    Introduced → Referred to House Health → No further action before the 118th Congress ended.

Committees

  1. HouseEnergy and CommerceReferred Feb 17, 2023
  2. HouseHealthReferred Feb 24, 2023
    1. Feb 29, 2024 · Hearing

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Titles (3)
  1. BENEFIT Act of 2023

    Display title, Short title · Introduced in House

  2. Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2023

    Short title · Introduced in House

  3. To strengthen the use of patient-experience data within the benefit-risk framework for approval of new drugs.

    Official title · Introduced in House